Soleno Therapeutics Inc (SLNO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.24 is considered Undervalued compared with the five-year average of -5.16. The fair price of Soleno Therapeutics Inc (SLNO) is between 318.79 to 579.44 according to relative valuation method. Compared to the current price of 39.06 USD , Soleno Therapeutics Inc By Undervalued By 87.75%.

Relative Value

Fair Zone

318.79-579.44

Current Price：39.06

87.75%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Soleno Therapeutics Inc (SLNO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Soleno Therapeutics Inc (SLNO) has a current Price-to-Book (P/B) ratio of 5.12. Compared to its 3-year average P/B ratio of 10.16, the current P/B ratio is approximately -49.61% higher. Relative to its 5-year average P/B ratio of 6.63, the current P/B ratio is about -22.80% higher. Soleno Therapeutics Inc (SLNO) has a Forward Free Cash Flow (FCF) yield of approximately -1.02%. Compared to its 3-year average FCF yield of -15.28%, the current FCF yield is approximately -93.31% lower. Relative to its 5-year average FCF yield of -49.94%, the current FCF yield is about -97.95% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SLNO competitors is 211.43, providing a benchmark for relative valuation. Soleno Therapeutics Inc Corp (SLNO.O) exhibits a P/S ratio of 6.24, which is -97.05% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SLNO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SLNO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SLNO currently overvalued or undervalued?

Soleno Therapeutics Inc (SLNO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.24 is considered Undervalued compared with the five-year average of -5.16. The fair price of Soleno Therapeutics Inc (SLNO) is between 318.79 to 579.44 according to relative valuation method. Compared to the current price of 39.06 USD, Soleno Therapeutics Inc is Undervalued By 87.75%.

What is Soleno Therapeutics Inc (SLNO) fair value?

SLNO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Soleno Therapeutics Inc (SLNO) is between 318.79 to 579.44 according to relative valuation method.

How does SLNO's valuation metrics compare to the industry average?

The average P/S ratio for SLNO's competitors is 211.43, providing a benchmark for relative valuation. Soleno Therapeutics Inc Corp (SLNO) exhibits a P/S ratio of 6.24, which is -97.05% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Soleno Therapeutics Inc (SLNO) as of Mar 03 2026?

As of Mar 03 2026, Soleno Therapeutics Inc (SLNO) has a P/B ratio of 5.12. This indicates that the market values SLNO at 5.12 times its book value.

What is the current FCF Yield for Soleno Therapeutics Inc (SLNO) as of Mar 03 2026?

As of Mar 03 2026, Soleno Therapeutics Inc (SLNO) has a FCF Yield of -1.02%. This means that for every dollar of Soleno Therapeutics Inc's market capitalization, the company generates -1.02 cents in free cash flow.

What is the current Forward P/E ratio for Soleno Therapeutics Inc (SLNO) as of Mar 03 2026?

As of Mar 03 2026, Soleno Therapeutics Inc (SLNO) has a Forward P/E ratio of 13.94. This means the market is willing to pay $13.94 for every dollar of Soleno Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Soleno Therapeutics Inc (SLNO) as of Mar 03 2026?

As of Mar 03 2026, Soleno Therapeutics Inc (SLNO) has a Forward P/S ratio of 6.24. This means the market is valuing SLNO at $6.24 for every dollar of expected revenue over the next 12 months.

SLNO Valuation